S
S

Serco

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

UK Stocks-Factors to watch on Aug 4

Aug 4 (Reuters) - Britain's FTSE 100 index .FTSE is seen opening higher on Thursday, with futures FFIc1 up 0.06%. * GLENCORE: Glencore GLEN.L announced a share buyback of $3 billion, after it reported a record half-yearly profit. * CENTAMIN: Gold miner Centamin Plc CEY.L reported a 4% rise in its first-half revenue. * GO AHEAD: Go-Ahead Group GOG.L agreed to an increased buyout offer from Australia's Kinetic Holding and Spain-based Globalvia Inversiones.
C
E
G
H
M
M
N
S
R
U

UK Stocks-Factors to watch on Aug 4

Aug 4 (Reuters) - Britain's FTSE 100 index .FTSE is seen opening higher on Thursday, with futures FFIc1 up 0.1%. * UNILEVER: Ben & Jerry's independent board said parent company Unilever Plc, ULVR.L with which it is locked in a dispute over the sale of its Israeli business, had frozen its directors' salaries in July as a pressure tactic ahead of a mediation on the matter.
C
E
G
H
M
M
N
S
R
U

UK Stocks-Factors to watch on May 26

May 26 (Reuters) - Britain's FTSE 100 index .FTSE is seen opening lower on Thursday, with futures FFIc1 down 0.1%. * JOHNSON MATTHEY: British chemicals maker Johnson Matthey Plc JMAT.L forecast 2022-23 operating profit at the lower half of market estimates on Thursday, as supply disruptions due to China's lockdowns and component sourcing from Ukraine hurt its auto customers.
I
S
J
U
U

UK Stocks-Factors to watch on Feb 24

Feb 24 (Reuters) - Britain's FTSE 100 index .FTSE is seen opening lower on Thursday, with futures FFIc1 down 3.32%. * BAE SYSTEMS: BAE Systems BAES.L forecast another year of sales growth and margin expansion in 2022 after reporting a 13% increase in 2021 core earnings. * ROLLS-ROYCE: Rolls-Royce RR.L expects to return to positive cash flow in 2022, which it said would be the final year with Warren East at the helm.
A
B
B
B
C
C
D
H
I
L
S
W
A
R
U

UK Stocks-Factors to watch on Feb 24

Feb 24 (Reuters) - Britain's FTSE 100 index .FTSE is seen opening lower on Thursday, with futures FFIc1 down 2.04%. * SANOFI-GSK: French drugmaker Sanofi SASY.PA and its British partner GlaxoSmithKline GSK.L are seeking regulatory approval for their COVID-19 vaccine to be used as a booster, as well as a standalone two-dose shot, after several setbacks.
A
B
B
C
D
D
G
H
I
L
S
S
W
R
U

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.